Clinical trials: Covid19 Vaccine
COVID-19
Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older
The primary objectives of the study are: To describe the safety profile of all participants in each age group and each study intervention group up to 12 months post-last dose.
- Trial name
- VAW00001 (NCT04798027)
- Testing
- SARS-CoV-2 mRNA vaccine formulation 1, SARS-CoV-2 mRNA vaccine formulation 2, SARS-CoV-2 mRNA vaccine formulation 3
- Where
- 21 sites in United States, Australia and 2 more
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
COVID-19
A Phase I/II Study of GLB-COV2-043 as a COVID-19 Vaccine Booster
The scope of this Phase I/II study is to determine whether GLB-COV2-043 is a promising booster vaccine candidate component for adult participants who have received the 2-dose priming course of the mRNA BNT162b2 vaccine against…
- Trial name
- NCT05602961
- Testing
- GLB-COV2-043, BNT162b2/COMIRNATY®
- Volunteers
- healthy volunteers welcome
- Sponsor
- GreenLight Biosciences, Inc.
Safety, Immunogenicity, Vaccine
Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23
The main objective of this study was to evaluate the immunogenicity and safety of the booster dose of COVID-19 inactivated vaccine and co-immunization with quadrivalent influenza vaccine and 23-valent pneumonia polysaccharide…
- Conditions
- Safety, Immunogenicity, Vaccine, COVID-19 Vaccines, Influenza Vaccines
- Trial name
- QIV;PPV23 (NCT05298800)
- Testing
- Vaccine
- Where
- 3 sites in China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention, China
COVID-19 Vaccines
Comparative Evaluation of Covid-19 Vaccines Response
Study Population Population with vaccinated with three different Covid Vaccines (Inactive Vaccine (Sinovac Life Sciences, Beijing, China), recombinant human adenovirus serotype number 26 (rAd26 of Sputnik V), mRNA Vaccine…
- Trial name
- NCT04895007
- Testing
- Covid-19 Inactive Vaccine, recombinant human adenovirus serotype number 26, mRNA VAccine
- Where
- 4 sites in Turkey (Türkiye)
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Karamanoğlu Mehmetbey University
SARS-CoV2 Infection
Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated Vaccine
This phase III trial aims to assess the efficacy, safety and immunogenicity of SARS-CoV-2 Vaccine (inactivated) and lot-to-lot consistency evaluation
- Trial name
- COVID-19 (NCT04508075)
- Testing
- SARS-CoV-2 vaccine (inactivated)
- Where
- Indonesia
- Volunteers
- 1,620 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
COVID-19
Phase I Clinical Trial With New SARS-CoV-2 CoVacHGMix Type 5 Adenoviral Vector Vaccine
The CoVacHGMix adenoviral vector vaccine is a new vaccine developed to protect against SARS-CoV-2 and is a Phase I study designed based on adaptive clinical trial standards.
- Trial name
- NCT05526183
- Testing
- Adeno-viral vector vaccine
- Where
- Turkey (Türkiye)
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Ankara City Hospital Bilkent
Covid19, Vaccine Reaction
Post COVID-19 Vaccination Analysis in Healthcare Worker Recipients
This research study is studying how healthcare worker recipients react after receiving vaccinations for COVID-19. The objective of the study is to evaluate the immune response to COVID-19 vaccination.
- Trial name
- NCT04922944
- Testing
- COVID-19 vaccine
- Where
- United States
- Volunteers
- 167 people
- Sponsor
- Huntington Memorial Hospital
SARS-CoV-2 Infection
A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine
The purpose of this study is to assess SARS CoV-2 infection, viral shedding, and subsequent potential transmission in individuals immunized with the Moderna COVID-19 vaccine.
- Trial name
- CoVPN 3006 (NCT04811664)
- Testing
- Moderna COVID-19 Vaccine
- Where
- 51 sites in United States
- Volunteers
- 1,923 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
Safety and Immunogenicity Study of Booster Vaccination With COVID-19 Vaccine (Vero Cell),Inactivated From Different Manufactures for Prevention of COVID-19
This is a randomized, Open, control phase Ⅳ clinical trial of inactivated COVID-19 vaccine manufactured by Sinovac Research \& Development Co., Ltd,Beijing institute of Biological Products Co.,Ltd and Wuhan Institute of…
- Trial name
- NCT05165732
- Testing
- Experimental vaccine 1, Experimental vaccine 2, Experimental vaccine 3
- Where
- China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
COVID-19 Immunisation, Influenza Vaccine
Evaluation of a Multilevel Intervention on Adult COVID-19 and Influenza Vaccination Rate
The study will test two tactics to improve uptake of two vaccines in adults. The vaccines prevent COVID-19 and influenza. Both are common and harmful. Most adults do not get either vaccine.
- Trial name
- NCT06646406
- Testing
- Patient letter and clinician communication
- Where
- 2 sites in United States
- Volunteers
- 114,165 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Old Age; Debility, Vaccine Hesitancy
COVID-19 Vaccination Willingness in Older Adults Based on Self-determination Theory
Introduction: The COVID-19 vaccine is an effective measure for preventing and controlling COVID-19 epidemics, and the World Health Organization lists older adults as a high-priority group for COVID-19 vaccination.
- Conditions
- Old Age; Debility, Vaccine Hesitancy, Vaccine Refusal
- Trial name
- CVWIOABOSDT (NCT06575114)
- Testing
- Self-determination theory-based health education measures
- Where
- China
- Volunteers
- 264 people, healthy volunteers welcome
- Sponsor
- Jing-Shan Deng
SARS-CoV-2 Infection
COVID-19 Paediatric VLA2001-321 Study
This is a Randomized, Double-blinded, Active-controlled Study to evaluate the Safety, Tolerability and Immunogenicity of VLA2001 in participants of ≥2 to 12 years.
- Trial name
- NCT05298644
- Testing
- VLA2001, Active Comparator
- Volunteers
- healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Hemolysis, COVID-19
Immunogenicity and Safety of BBIBP-Corv Coadministered With PPV23 and IIV4 in Hemodialysis Population
Evaluation of immunogenicity and safety of inactivated COVID-19 vaccine (BBIBP-Corv) coadministered with PPV23 and IIV4 in hemodialysis population.
- Trial name
- NCT05480436
- Testing
- coadministration, COVID-19 vaccine, IIV4+PPV23
- Where
- 3 sites in China
- Volunteers
- 1,200 people
- Sponsor
- China National Biotec Group Company Limited
Venous Thromboembolism
Venous Thromboembolism During COVID-19 Pandemic: Evaluation of the Association With the Vaccine and COVID-19 Infection
Observational, spontaneous, retrospective, multicenter national study for adult patients, not hospitalized, attending the Thrombo-Embolic Emergency Clinic of the Angiology and Coagulation Disorders Unit (SSD Angiologia e Malattie…
- Trial name
- NCT06806800
- Where
- Italy
- Volunteers
- 16,000 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Microbiome, Vaccine
Gut Microbiota, the Potential Key to Modulating Humoral Immunogenicity of New Platform COVID-19 Vaccines
Vaccination is the best way to mitigate the coronavirus disease 2019 (COVID-19) pandemic, but the vaccine immunogenicity may be quite variable from person to person.
- Conditions
- Microbiome, Vaccine, Covid-19, SARS-CoV-2
- Trial name
- NCT05150834
- Testing
- This is observational study
- Where
- South Korea
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Korea University Guro Hospital
COVID-19 (Healthy Volunteers)
Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 (COVID-19)
This is a first-in-human, Phase I/II, randomized, placebo-controlled, observer-blinded, age-escalating study to assess the safety, reactogenicity and immunogenicity of a SK SARS-CoV-2 recombinant protein nanoparticle vaccine…
- Trial name
- NCT04750343
- Testing
- GBP510 adjuvanted with AS03 (RBD 10μg/dose) - Stage 1, GBP510 (RBD 10μg/dose) - Stage 1, Normal saline (0.9% sodium chloride solution) - Stage 1
- Where
- 14 sites in South Korea
- Volunteers
- 328 people, healthy volunteers welcome
- Sponsor
- SK Bioscience Co., Ltd.
Vaccine Reaction, COVID-19
Determining Reactogenicity and Immunogenicity of Delayed COVID-19 Vaccine Schedule in Children
COVID-19 vaccine response data in children 5 to 11 years old remain scarce. Our understanding of the safety and immune responses including humoral and cellular responses generated in children remains limited.
- Conditions
- Vaccine Reaction, COVID-19, Children, Only
- Trial name
- NCT05329064
- Testing
- BNT162b2 Pfizer-BioNTech/Comirnaty
- Where
- Singapore
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- KK Women's and Children's Hospital
Liver Diseases, Covid19
Safety and Immune Response of COVID-19 Vaccination in Patients With Chronic Liver Diseases
On 11 February 2020, the International Committee for the Classification of Viruses named the disease caused by SAＲS-CoV-2 infection in humans as the new coronavirus pneumonia (coronavirus disease 2019, COVID-19).
- Conditions
- Liver Diseases, Covid19, Adverse Reaction to Vaccine
- Trial name
- SIMPLE (NCT05007665)
- Testing
- SARS-COV-2 VACCINE
- Where
- China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
COVID-19, Sars-CoV-2 Infection
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E in Population Aged ≥18 Years Previously Fully Vaccinated With mRNA COVID-19 Vaccine
The objective of this study is to evaluate the immunogenicity and safety of SCTV01E in participants aged ≥18 years and previously fully immunized with mRNA COVID-19 vaccine.
- Trial name
- NCT05238441
- Testing
- SCTV01E, Comirnaty
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
COVID-19
Safety and Immunogenicity of EXG-5003
This is a First in Human, randomized, placebo-controlled Phase I/II trial to evaluate the safety and immunogenicity of the intradermal COVID-19 vaccine, EXG-5003 in healthy adults.
- Trial name
- NCT04863131
- Testing
- EXG-5003
- Where
- Japan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Fujita Health University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.